EUCTR2007-002771-14-AT进行中（未招募）不适用
COMPARISON OF THREE COMMERCIAL BATCHES OF THE JAPANESE ENCEPHALITIS VACCINE IC51. DOUBLE BLIND, RANDOMIZED, CONTROLLED PHASE 3 STUDY
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Intercell AG
- 入组人数
- 384
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- At least 18 years of age
- •- In female subjects, either childbearing potential terminated by surgery or 1 year post menopausal, or a negative serum pregnancy test during screening and the willingness not to become pregnant during the entire study period by practicing reliable methods of contraception, as specified in protocol Section 6.4
- •- Written informed consent obtained prior to study entry (subjects should give their consent themselves)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- History of clinical manifestation of any flavivirus infection
- •- History of vaccination against JE (including study participation in any previous or current IC51 clinical study), Yellow fever and Dengue fever
- •- Use of any other investigational or non-registered drug or vaccine in addition to the study vaccine during the study period or within 30 days preceding the first dose of study vaccine
- •- Administration of any other vaccine within 4 weeks before randomization and during the study period
- •- Immunodeficiency including post-organ-transplantation or immunosuppressive therapy
- •- A family history of congenital or hereditary immunodeficiency
- •- History of autoimmune disease
- •- Administration of chronic (defined as more than 14 days) immunosuppressants or other immune-modifying drugs within 6 months of vaccination. (For corticosteroids, this will mean prednisone, or equivalent, >/= 0.05 mg/kg/day. Topical and inhaled steroids are allowed.)
- •- Any acute infections within 4 weeks prior to randomization
- •- History of severe hypersensitivity reactions, in particular to a component of the IC51 vaccine (e.g. protamine sulfate), anaphylaxis or severe cases of atopy requiring emergency treatment or hospital admission
- •- Infection with HIV (a negative test result within 30 days before screening is acceptable), HBV (Hepatitis B surface antigen [HBsAg]) or HCV
- •- History of urticaria after hymenoptera envenomation, drugs, physical or other provocations, or of idiopathic cause
- •- Drug addiction within 6 months prior to enrollment (including alcohol dependence, i.e. more than approximately 60 g alcohol per day, or conditions which might interfere with the study conduct)
- •- Inability or unwillingness to avoid more than the usual intake of alcohol during the 48 hours after vaccination
- •- Diabetes mellitus in subjects receiving insulin therapy, severe cardiopulmonary disorders, or history of malignancy in the past 5 years
- •- Pregnancy (positive pregnancy test during screening or at baseline), lactation or unreliable contraception in female subjects with child-bearing potential (for details, please refer to Section 6.4)
- •- Subjects with any condition which in the opinion of the investigator makes the subject unsuitable for inclusion
- •- Inability or unwillingness to provide informed consent and to abide by the requirements of the study
- •- Persons who have been committed to an institution (by a court or by an authority) will not participate in the study
研究者
相似试验
进行中（未招募）
不适用
COMPARISON OF THREE COMMERCIAL BATCHES OF THE JAPANESE ENCEPHALITIS VACCINE IC51. DOUBLE BLIND, RANDOMIZED, CONTROLLED PHASE 3 STUDYEUCTR2007-002771-14-DEIntercell AG384
进行中（未招募）
不适用
COMPARISON OF THREE BATCHES OF THE JAPANESE ENCEPHALITIS VACCINE IC51 (JE-PIV). DOUBLE BLIND, RANDOMIZED, CONTROLLED PHASE 3 STUDY.Japanese encephalitisEUCTR2006-002076-18-DEIntercell AG624
进行中（未招募）
不适用
COMPARISON OF THREE BATCHES OF THE JAPANESE ENCEPHALITIS VACCINE IC51 (JE-PIV). DOUBLE BLIND, RANDOMIZED, CONTROLLED PHASE 3 STUDY.Japanese encephalitisEUCTR2006-002076-18-ATIntercell AG624
已完成
3 期
Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51Japanese EncephalitisNCT00595465Valneva Austria GmbH389
已完成
不适用
The comparison of the characteristics of Japanese SCCmec type II and type IV MRSA.MRSA infectionJPRN-UMIN000023232Department of General Internal Medicine, Kyushu University Hospital280